Niche play, alliances hold promise for Biocon

New Drug Approvals

 DR KIRAN SHAW MAXUMDAR

MD BIOCON

While biosimilar opportunity in the regulated markets is likely to play out in the medium term, its existing biopharma and branded portfolio will ensure growth in the short term

Niche play, alliances hold promise for Biocon
Business Standard
Innovator sales for these two drugs are pegged at $10 billion which is slightly over half of the worldwide insulin market of $19 billion.On the monoclonal antibody front, the company is in phase III for the cancer drug Trastuzumab which has a market …

READ ALL THIS AT

http://www.business-standard.com/article/companies/niche-play-alliances-hold-promise-for-biocon-113090500095_1.html

 

View original post